bioRxivCancer BiologyPreprint
Pentose Phosphate Pathway Inhibition activates Macrophages towards phagocytic Lymphoma Cell Clearance
A. C. Beielstein, E. Izquierdo, S. J. Blakemore, N. Nickel, M. Michalik, S. Chawan, R. Brinker, H.-H. Bartel, D. Vorholt, J. L. Nolte, R. Linke, C. R. Costa Picosi, J. Saiz, F. Picard, J. Meinel, R. Buettner, A. Villasenor, H. Winkels, M. Hallek, M. Krueger, C. Barbas, C. P. Pallasch
Abstract
Macrophages in the B-cell lymphoma microenvironment represent a functional node in progression and therapeutic response. We assessed metabolic regulation of macrophages in the context of therapeutic antibody-mediated phagocytosis. Pentose phosphate pathway (PPP) inhibition by specific compounds and shRNA targeting induced increased phagocytic lymphoma cell clearance. Moreover, macrophages provided decreased support for survival of lymphoma cells. PPP inhibition induced metabolic activation, cytoskeletal re-modelling and pro-inflammatory polarization of macrophages. A link between PPP and immune regulation was identified as mechanism of macrophage repolarization. Inhibition of the PPP causes suppression of glycogen synthesis and subsequent modulation of the immune modulatory UDPG-Stat1-Irg1-Itaconate axis. PPP inhibition rewired macrophage maturation and activation in vivo. Addition of the PPP inhibitor S3 to antibody therapy achieved significantly prolonged overall survival in an aggressive B-cell lymphoma mouse model. We hypothesize the PPP as key regulator and targetable modulator of macrophage activity in lymphoma to improve efficacy of immunotherapies. HighlightsO_LIMacrophage-mediated lymphoma cell phagocytosis is increased by pentose phosphate pathway (PPP) inhibition as an immune regulatory switch for macrophage function and polarization C_LIO_LIPPP inhibition is linked to decreased glycogen synthesis and subsequent modulation of the UDPG-Stat1-Irg1-Itaconate axis C_LIO_LIPPP inhibition is tolerable in vivo and facilitates therapeutic targeting of B-cell lymphoma C_LI
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Macrophage Activation by a Substituted PyrimidoIndole Increases Anti-Cancer Activity
J. Hardie, J. A. Mas-Rosario, … M. E. Farkas·bioRxiv·Mar 18, 2019
- Immunomodulatory mechanisms of submicron phosphatidylserine-exposing polymeric particles (PSPs)
Maria Thea Rane Dela Cruz Clarin, Kenichi Kimura, … Hiromi Yanagisawa·bioRxiv·Aug 10, 2026
- Pre-Clinical Blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
C. Vincent-Fabert, L. Roland, … N. Faumont·bioRxiv·Dec 21, 2018
- Focal adhesion pathway inhibition is the central axis of macrophage phenotypic responses to monoclonal antibody therapy in aggressive lymphoma via high-throughput screening and high-content imaging
Stuart James Blakemore, Peter Zentis, … Christian Philipp Pallasch·bioRxiv·Sep 23, 2025
- Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer
K. Chaudagar, H. M. Hieromnimon, … A. Patnaik·bioRxiv·May 12, 2022
- Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation
E. C. Suter, E. M. Schmid, … D. A. Fletcher·bioRxiv·Jul 31, 2020